Article, 2024

Clinical trial evaluation: the EDOSURE clinical trial program

Future Cardiology, ISSN 1744-8298, 1479-6678, Volume ahead-of-print, ahead-of-print, Pages 1-7, 10.1080/14796678.2024.2354079

Contributors

Griffin, Michael (Corresponding author) [1] Lip, Gregory YH [1] [2]

Affiliations

  1. [1] University of Liverpool
    2. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  2. [2] Aalborg University
    3. [NORA names: AAU Aalborg University; University; Denmark; Europe, EU; Nordic; OECD]

Abstract

EDOSURE is a trial program of the direct oral anticoagulant drug edoxaban, comprising ten randomized clinical trials of which eight are currently published. They evaluate the use of edoxaban in the treatment of nonvalvular atrial fibrillation and acute venous thromboembolism, including in special circumstances such as patients undergoing cardiac procedures, cancer-associated venous thromboembolism, and elderly patients whose bleeding risk precludes conventional anticoagulation strategies. As a result of the collective evidence generated by EDOSURE, edoxaban is now recommended as a treatment option by numerous international guidelines. This review summarizes the context, rationale, and key findings of the studies.

Keywords

acute venous thromboembolism, anticoagulant drugs, anticoagulation strategies, atrial fibrillation, bleeding risk, cardiac procedures, clinical trials, context, conventional anticoagulation strategy, drug, edoxaban, elderly patients, evidence, fibrillation, findings, guidelines, international guidelines, nonvalvular atrial fibrillation, options, oral anticoagulant drugs, patients, procedure, program, randomized clinical trials, rationale, review, risk, strategies, study, thromboembolism, treatment, treatment of nonvalvular atrial fibrillation, treatment options, trial program, trials, venous thromboembolism

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+